Literature DB >> 18161050

Etiology-dependent molecular mechanisms in human hepatocarcinogenesis.

Christof Schlaeger1, Thomas Longerich, Claudia Schiller, Peter Bewerunge, Arianeb Mehrabi, Grischa Toedt, Jörg Kleeff, Volker Ehemann, Roland Eils, Peter Lichter, Peter Schirmacher, Bernhard Radlwimmer.   

Abstract

UNLABELLED: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and is characterized by aggressive tumor behavior coupled with poor prognosis. Various etiologies have been linked to HCC development, most prominently chronic hepatitis B and C virus infections as well as chronic alcohol consumption. In approximately 10% of HCCs, the etiology remains cryptic; however, recent epidemiological data suggest that most of these cryptogenic HCCs develop due to nonalcoholic steatohepatitis. To identify etiology-dependent DNA copy number aberrations and genes relevant to hepatocarcinogenesis, we performed array-based comparative genomic hybridization of 63 HCCs of well-defined etiology and 4 HCC cell lines followed by gene expression profiling and functional analyses of candidate genes. For a 10-megabase chromosome region on 8q24, we observed etiology-dependent copy number gains and MYC overexpression in viral and alcohol-related HCCs, resulting in up-regulation of MYC target genes. Cryptogenic HCCs showed neither 8q24 gains, nor MYC overexpression, nor target gene activation, suggesting that tumors of this etiology develop by way of a distinct MYC-independent pathomechanism. Furthermore, we detected several etiology-independent small chromosome aberrations, including amplification of MDM4 on 1q32.1 and frequent gains of EEF1A2 on 20q13.33. Both genes were overexpressed in approximately half the HCCs examined, and gene silencing reduced cell viability as well as proliferation and increased apoptosis rates in HCC cell lines.
CONCLUSION: Our findings suggest that MDM4 and EEF1A2 act as etiology-independent oncogenes in a significant percentage of HCCs.

Entities:  

Mesh:

Year:  2008        PMID: 18161050     DOI: 10.1002/hep.22033

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  76 in total

Review 1.  [EEF1A2 inhibits the p53 function in hepatocellular carcinoma via PI3K/AKT/mTOR-dependent stabilization of MDM4].

Authors:  T Longerich
Journal:  Pathologe       Date:  2014-11       Impact factor: 1.011

2.  Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA.

Authors:  Jie Ding; Shenglin Huang; Shunquan Wu; Yingjun Zhao; Linhui Liang; Mingxia Yan; Chao Ge; Jian Yao; Taoyang Chen; Dafang Wan; Hongyang Wang; Jianren Gu; Ming Yao; Jinjun Li; Hong Tu; Xianghuo He
Journal:  Nat Cell Biol       Date:  2010-03-21       Impact factor: 28.824

3.  Clinical implication of recurrent copy number alterations in hepatocellular carcinoma and putative oncogenes in recurrent gains on 1q.

Authors:  Tae-Min Kim; Seon-Hee Yim; Seung-Hun Shin; Hai-Dong Xu; Yu-Chae Jung; Cheol-Keun Park; Jong-Young Choi; Won-Sang Park; Mi-Seon Kwon; Heike Fiegler; Nigel P Carter; Mun-Gan Rhyu; Yeun-Jun Chung
Journal:  Int J Cancer       Date:  2008-12-15       Impact factor: 7.396

4.  Translation control of the immune checkpoint in cancer and its therapeutic targeting.

Authors:  Yichen Xu; Mauro Poggio; Hyun Yong Jin; Zhen Shi; Craig M Forester; Ying Wang; Craig R Stumpf; Lingru Xue; Emily Devericks; Lomon So; Hao G Nguyen; Alice Griselin; John D Gordan; Sarah E Umetsu; Siegfried H Reich; Stephen T Worland; Saurabh Asthana; Maria Barna; Kevin R Webster; John T Cunningham; Davide Ruggero
Journal:  Nat Med       Date:  2019-01-14       Impact factor: 53.440

5.  Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma.

Authors:  Nicola Personeni; Lorenza Rimassa; Tiziana Pressiani; Annarita Destro; Claudia Ligorio; Maria Chiara Tronconi; Silvia Bozzarelli; Carlo Carnaghi; Luca Di Tommaso; Laura Giordano; Massimo Roncalli; Armando Santoro
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-09       Impact factor: 4.553

6.  EEF1A2 inactivates p53 by way of PI3K/AKT/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma.

Authors:  Rossella Pellegrino; Diego F Calvisi; Olaf Neumann; Venkatesh Kolluru; Josephine Wesely; Xin Chen; Chunmei Wang; Torsten Wuestefeld; Sara Ladu; Nahla Elgohary; Justo Lorenzo Bermejo; Bernhard Radlwimmer; Martin Zörnig; Lars Zender; Frank Dombrowski; Matthias Evert; Peter Schirmacher; Thomas Longerich
Journal:  Hepatology       Date:  2014-03-27       Impact factor: 17.425

7.  Sequential adaptive changes in a c-Myc-driven model of hepatocellular carcinoma.

Authors:  James M Dolezal; Huabo Wang; Sucheta Kulkarni; Laura Jackson; Jie Lu; Sarangarajan Ranganathan; Eric S Goetzman; Sivakama S Bharathi; Kevin Beezhold; Craig A Byersdorfer; Edward V Prochownik
Journal:  J Biol Chem       Date:  2017-04-21       Impact factor: 5.157

8.  Accomplishments in 2008 in the management of hepatobiliary cancers.

Authors:  Andrew X Zhu; Anthony El-Khoueiry; Josep M Llovet
Journal:  Gastrointest Cancer Res       Date:  2009-09

Review 9.  Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

Authors:  Mark Wade; Geoffrey M Wahl
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

Review 10.  The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology.

Authors:  Stephen Caldwell; Sang H Park
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.